Regulation, counter-regulation, and immunotherapy of autoimmune responses to immunologically privileged retinal antigens.
Our interests revolve around the study of biological mechanisms regulating self-tolerance to immunologically privileged retinal proteins that serve as targets in sight-threatening autoimmune uveitic disease. These studies are aimed at understanding how selftolerance to these antigens develops during ontogeny and is maintained during adulthood, the processes involved in its pathological breakdown, the regulatory mechanisms that bring about remission and recovery, and, finally, how we can utilize knowledge of these processes for therapeutic restoration of tolerance. To answer these questions, we use the experimental autoimmune uveitis (EAU) model in rats and mice. Because of the commonality of underlying immunological mechanisms, lessons and concepts learned in experimental ocular models are applicable to other disease entities, and, conversely, data gleaned from other autoimmune diseases are applicable to the study of uveitis.
Caspi
Rachel R
RR
Section on Immunoregulation, Laboratory of Immunology, National Eye Institute, NIH, Bethesda MD 20892-1857, USA rcapi@helix.nih.gov
D000818:Animals; D001327:Autoimmune Diseases / Q000628:therapy*; D004195:Disease Models, Animal; D020022:Genetic Predisposition to Disease; D006801:Humans; D007167:Immunotherapy; D012160:Retina / Q000276:immunology*; D017634:Self Tolerance / Q000276:immunology*; D014605:Uveitis / Q000235:genetics / Q000276:immunology / Q000628:therapy*